SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes

Blood

Volumn 102, Issue 3, 2003, Pages 795-801

  Giles, Francis J ^a   Stopeck, Alison T ^b   Silverman, Lewis R ^b   Lancet, Jeffrey E ^b   Cooper, Maureen A ^b   Hannah, Alison L ^b   Cherrington, Julie M ^b   O'Farrell, Anne Marie ^b   Yuen, Helene A ^b   Louie, Sharianne G ^b   Hong, Weiru ^b   Cortes, Jorge E ^b   Verstovsek, Srdan ^b   Albitar, Maher ^b   O'Brien, Susan M ^b   Kantarjian, Hagop M ^b   Karp, Judith E ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; CASTOR OIL; DIPHENHYDRAMINE; FAMOTIDINE; FLT3 LIGAND; HISTAMINE H1 RECEPTOR ANTAGONIST; HISTAMINE H2 RECEPTOR ANTAGONIST; RECEPTOR BLOCKING AGENT; SEMAXANIB; STEM CELL FACTOR; TYROSINE KINASE RECEPTOR; TYROSINE KINASE RECEPTOR INHIBITOR; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ABDOMINAL PAIN; ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; BONE PAIN; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DIARRHEA; DIGESTIVE SYSTEM FUNCTION DISORDER; DRUG EFFECT; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG STRUCTURE; DYSPNEA; ERYTHEMA; FATIGUE; FEMALE; FLUSHING; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPEROSMOLARITY; HYPOTENSION; INJECTION PAIN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYELODYSPLASTIC SYNDROME; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RELAPSE; SIDE EFFECT; SKIN INDURATION; SURVIVAL TIME; THROMBOEMBOLISM; THROMBOSIS; VOMITING;

EID: 0043245991     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-10-3023     Document Type: Article

References (60)

1. Aguayo A, Kantarjian H, Manshouri T, et al. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood. 2000;96: 2240-2245.
2. Bertolini F, Mancuso P, Gobbi A, et al. The thin red line: angiogenesis in normal and malignant hematopoiesis. Exp Hematol. 2000;28:993-1000.
3. Padro T, Ruiz S, Bieker R, et al. Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia. Blood. 2000;95:2637-2644.
4. Albitar M. Angiogenesis in acute myeloid leukemia and myelodysplastic syndrome. Acta Haematol. 2001;106:170-176.
5. Fiedler W, Graeven U, Ergun S, et al. Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia. Blood. 1997;89:1870-1875.
6. Fiedler W, Staib P, Kuse R, et al. Role of angiogenesis inhibitors in acute myeloid leukemia. Cancer J. 2001;7(suppl 3):S129-S133.
7. Hussong JW, Rodgers GM, Shami PJ. Evidence of increased angiogenesis in patients with acute myeloid leukemia. Blood. 2000;95:309-313.
8. Zachary I, Gliki G. Signaling transduction mechanisms mediating biological actions of the vascular endothelial growth factor family. Cardiovasc Res. 2001;49:568-581.
9. Benjamin LE, Keshet E. Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal. Proc Natl Acad Sci U S A. 1997;94:8761-8766.
10. Verstovsek S, Estey E, Manshouri T, et al. Clinical relevance of vascular endothelial growth factor receptors 1 and 2 in acute myeloid leukaemia and myelodysplastic syndrome. Br J Haematol. 2002; 118:151-156.
11. Clauss M. Molecular biology of the VEGF and the VEGF receptor family. Semin Thromb Hemost. 2000;26:561-569.
12. Padro T, Bieker R, Ruiz S, et al. Overexpression of vascular endothelial growth factor (VEGF) and its cellular receptor KDR (VEGFR-2) in the bone marrow of patients with acute myeloid leukemia. Leukemia. 2002;16:1302-1310.
13. Dias S, Hattori K, Zhu Z, et al. Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration. J Clin Invest. 2000;106: 511-521.
14. Bellamy WT, Richter L, Frutiger Y, et al. Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. Cancer Res. 1999;59:728-733.
15. Katoh O, Tauchi H, Kawaishi K, et al. Expression of the vascular endothelial growth factor (VEGF) receptor gene, KDR, in hematopoietic cells and inhibitory effect of VEGF on apoptotic cell death caused by ionizing radiation. Cancer Res. 1995; 55:5687-5692.
16. Giles FJ. The vascular endothelial growth factor (VEGF) signaling pathway: a therapeutic target in patients with hematologic malignancies. Oncologist. 2001;6:32-39.
17. Perez-Atayde AR, Sallan SE, Tedrow U, et al. Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia. Am J Pathol. 1997;150:815-821.
18. Aguayo A, Estey E, Kantarjian H, et al. Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia. Blood. 1999;94:3717-3721.
19. Mendel DB, Schreck RE, West DC, et al. The angiogenesis inhibitor SU5416 has long-lasting effects on vascular endothelial growth factor receptor phosphorylation and function. Clin Cancer Res. 2000;6:4848-4858.
20. Sukbuntherng J, Cropp G, Hannah A, et al. Pharmacokinetics and interspecies scaling of a novel VEGF receptor inhibitor, SU5416. J Pharm Pharmacol. 2001;53:1629-1636.
21. Fong TA, Shawver LK, Sun L, et al. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res. 1999;59:99-106.
22. Vajkoczy P, Menger MD, Vollmar B, et al. Inhibition of tumor growth, angiogenesis, and microcirculation by the novel Flk-1 inhibitor SU5416 as assessed by intravital multi-fluorescence video-microscopy. Neoplasia. 1999;1:31-41.
23. Shaheen RM, Davis DW, Liu W, et al. Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer liver metastasis and induces tumor and endothelial cell apoptosis. Cancer Res. 1999;59:5412-5416.
24. Ikeda H, Kanakura Y, Tamaki T, et al. Expression and functional role of the proto-oncogene c-kit in acute myeloblastic leukemia cells. Blood. 1991; 78:2962-2968.
25. Kuriu A, Ikeda H, Kanakura Y, et al. Proliferation of human myeloid leukemia cell line associated with the tyrosine-phosphorylation and activation of the proto-oncogene c-kit product. Blood. 1991; 78:2834-2840.
26. Sperling C, Schwartz S, Buchner T, et al. Expression of the stem cell factor receptor C-KIT (CD117) in acute leukemias. Haematologica. 1997;82:617-621.
27. Bene MC, Bernier M, Casasnovas RO, et al. The reliability and specificity of c-kit for the diagnosis of acute myeloid leukemias and undifferentiated leukemias: the European Group for the Immunological Classification of Leukemias (EGIL). Blood. 1998;92:596-599.
28. Meyer C, Drexler HG. FLT3 ligand inhibits apoptosis and promotes survival of myeloid leukemia cell lines. Leuk Lymphoma. 1999;32:577-581.
29. Smolich BD, Yuen HA, West KA, et al. The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the SCF receptor (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts. Blood. 2001;97:1413-1421.
30. Fenski R, Flesch K, Serve S, et al. Constitutive activation of FLT3 in acute myeloid leukaemia and its consequences for growth of 32D cells. Br J Haematol. 2000;108:322-330.
31. Mizuki M, Fenski R, Halffer H, et al. Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways. Blood. 2000;96: 3907-3914.
32. Tse KF, Mukherjee G, Small D. Constitutive activation of FLT3 stimulates multiple intracellular signal transducers and results in transformation. Leukemia. 2000;14:1766-1776.
33. Kiyoi H, Naoe T, Nakano Y, et al. Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood. 1999;93:3074-3080.
34. Nakao M, Yokota S, Iwai T, et al. Internal tandem duplication of the fit3 gene found in acute myeloid leukemia. Leukemia. 1996;10:1911-1918.
35. Rombouts WJ, Blokland I, Lowenberg B, et al. Biological characteristics and prognosis of adult acute myeloid leukemia with internal tandem duplications in the Flt3 gene. Leukemia. 2000;14: 675-683.
36. Kottaridis PD, Gale RE, Frew ME, et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood. 2001;98: 1752-1759.
37. Yee KW, O'Farrell AM, Smolich BD, et al. SU5416 and SU5614 inhibit kinase activity of wild type and mutant FLT3 receptor tyrosine kinase. Blood. 2002;100:2941-2949.
38. Albitar M, Manshouri T, Shen Y, et al. Myelodysplastic syndrome is not merely "preleukemia." Blood. 2002;100:791-798.
39. Mesters RM, Padro T, Bieker R, et al. Stable remission after administration of the receptor tyrosine kinase inhibitor SU5416 in a patient with refractory acute myeloid leukemia. Blood. 2001; 98:241-243.
40. Gelderblom H, Verweij J, Nooter K, et al. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer. 2001;37:1590-1598.
41. Michaud LB. Methods for preventing reactions secondary to Cremophor EL. Ann Pharmacother. 1997;31:1402-1404.
42. Stopeck A, Sheldon M, Vahedian M, et al. Results of a phase I dose-escalating study of the antiangiogenic agent, SU5416, in patients with advanced malignancies. Clin Cancer Res. 2002;8: 2798-2805.
43. Antonian L, Zhang H, Yang C, et al. Biotransformation of the anti-angiogenic compound SU5416. Drug Metab Dispos. 2000;28:1505-1512.
44. Singer MI, Shapiro LE, Shear NH. Cytochrome P-450 3A: interactions with dermatologic therapies. J Am Acad Dermatol. 1997;37:765-771.
45. Amsden GW. Macrolides versus azalides: a drug interaction update. Ann Pharmacother. 1995;29: 906-917.
46. Maskalyk J. Grapefruit juice: potential drug interactions. CMAJ. 2002;167:279-280.
47. Estey E, Thall P, David C. Design and analysis of trials of salvage therapy in acute myelogenous leukemia. Cancer Chemother Pharmacol. 1997; 40:S9-S12.
48. SUGEN I: SU5416 Investigator Brochure. November 28. South San Francisco, CA: Sugen; 2001.
49. Spiekermann K, Faber F, Voswinckel R, et al. The protein tyrosine kinase inhibitor SU5614 inhibits VEGF-induced endothelial cell sprouting and induces growth arrest and apoptosis by inhibition of c-kit in AML cells. Exp Hematol. 2002;30:767-773.
50. Forbes LV, Gale RE, Pizzey A, et al. An activating mutation in the transmembrane domain of the granulocyte colony-stimulating factor receptor in patients with acute myeloid leukemia. Oncogene. 2002;21:5981-5989.
51. Boissel N, Cayuela JM, Preudhomme C, et al. Prognostic significance of FLT3 internal tandem repeat in patients with de novo acute myeloid leukemia treated with reinforced courses of chemotherapy. Leukemia. 2002;16:1699-1704.
52. Gilliland DG, Griffin JD. The roles of FLT3 in hematopoiesis and leukemia. Blood. 2002;100: 1532-1542.
53. Kuenen BC, Rosen L, Smit EF, et al. Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors. J Clin Oncol. 2002;20:1657-1667.
54. Rosen P, Amado R, Hecht J. A phase I/II study of SU5416 in combination with 5-FU/leucovorin in patients with metastatic colorectal cancer [abstract]. Proc Am Soc Clin Oncol. 2000;19:3A.
55. Rosen P, Kabbinavar F, Figlin R. A phase I/II trial and pharmacokinetic study of SU5416 in combination with paclitaxel/carboplatin [abstract 389]. Proc Am Soc Clin Oncol. 2001;20:98a.
56. Fledler WM, Tinnefeld H, Mende T, et al. A phase II study with SU5416 in patients with c-kit positive AML [abstract]. Proc Am Soc Clin Oncol. 2001; 20:288a.
57. Haroon ZA, Amin K, Saito W, et al. SU5416 delays wound healing through inhibition of TGF-beta 1 activation. Cancer Biol Ther. 2002;1:121-126; discussion 127-129.
58. Gelaw B, Levin S. Wound-induced angiogenesis and its pharmacologic inhibition in a murine model. Surgery. 2001;130:497-501.
59. Roman CD, Choy H, Nanney L, et al. Vascular endothelial growth factor-mediated angiogenesis inhibition and postoperative wound healing in rats. J Surg Res. 2002;105:43-47.
60. McCarty ME, Ellis LM. Mechanisms of anti-angiogenic tyrosine kinase inhibition on wound healing - the obvious and not so obvious. Cancer Biol Ther. 2002;1:127-129.